Investment Analysts’ Recent Ratings Updates for Spruce Biosciences (SPRB)

A number of research firms have changed their ratings and price targets for Spruce Biosciences (NASDAQ: SPRB):

• 6/9/2026 – Spruce Biosciences is now covered by JonesTrading. They set a “buy” rating and a $135.00 price target on the stock.
• 6/5/2026 – Spruce Biosciences had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 6/1/2026 – Spruce Biosciences had its price target lowered by HC Wainwright from $200.00 to $150.00. They now have a “buy” rating on the stock.
• 5/27/2026 – Spruce Biosciences had its “outperform” rating reaffirmed by Oppenheimer Holdings, Inc..
• 5/14/2026 – Spruce Biosciences had its price target lowered by Citizens Jmp from $170.00 to $150.00. They now have a “market outperform” rating on the stock.
• 4/27/2026 – Spruce Biosciences is now covered by Craig Hallum. They set a “buy” rating and a $140.00 price target on the stock.

Spruce Biosciences, Inc is a clinical-stage biopharmaceutical company dedicated to developing therapies for rare endocrine and dermatological disorders. Headquartered in San Diego, California, Spruce focuses on conditions with significant unmet medical needs, employing a precision medicine approach to identify and advance treatment candidates through late-stage clinical trials.

The company’s lead asset, tildacerfont, is an oral corticotropin-releasing factor type 1 (CRF1) receptor antagonist being evaluated for the treatment of congenital adrenal hyperplasia (CAH), a genetic disorder characterized by insufficient cortisol production and excess androgen levels.